Posts by: Timea Polgar

Timea Polgar

Timea is a Molecular biologist (MSc) & Computational chemist (MSc, PhD), science liaison, and strategic business development and marketing specialist, with 15 years in pharmaceutical R&D, biotech and scientific software development.

April 20, 2016

Basil Receives Up to $100M For Work Leading to FDA Approval of Pneumonia Drug

Basilea Pharmaceutica and the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, announced they have agreed on the details of Basilea’s wide-spectrum ... Read more

April 18, 2016April 18, 2016

Thrombomodulin May Be Effective Treatment for Acute Exacerbations in Nonspecific Interstitial Pneumonia and IPF

New research supported the efficacy of the recombinant human soluble thrombomodulin (rhTM) for the treatment of acute exacerbation (AE) resulting from idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), but further studies ... Read more

April 15, 2016

Basilea Presents Data on Studies into Fungal and Pneumonia Treatments at ECCMID

Basilea Pharmaceutica, Ltd., presented scientific data on its antifungal treatment isavuconazole (Cresemba) and antibiotic ceftobiprole (Zevtera) in a number of poster and oral presentations at the European Congress of Clinical Microbiology and Infectious ... Read more